Literature DB >> 24402926

Ariad suspends ponatinib sales.

.   

Abstract

Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chronic myeloid leukemia in patients resistant to first-line therapy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24402926     DOI： 10.1158/2159-8290.CD-NB2013-163

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

Review 1.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

2.  Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization.

Authors:  Sanil Bhatia; Lukas Spanier; David Bickel; Niklas Dienstbier; Vitalij Woloschin; Melina Vogt; Henrik Pols; Beate Lungerich; Jens Reiners; Narges Aghaallaei; Daniela Diedrich; Benedikt Frieg; Julian Schliehe-Diecks; Bertan Bopp; Franziska Lang; Mohanraj Gopalswamy; Jennifer Loschwitz; Baubak Bajohgli; Julia Skokowa; Arndt Borkhardt; Julia Hauer; Finn K Hansen; Sander H J Smits; Joachim Jose; Holger Gohlke; Thomas Kurz
Journal:  ACS Cent Sci       Date:  2022-04-27       Impact factor: 18.728

3.  Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Authors:  M S Zabriskie; C A Eide; D Yan; N A Vellore; A D Pomicter; S L Savage; B J Druker; M W Deininger; T O'Hare
Journal:  Leukemia       Date:  2015-11-19       Impact factor: 11.528

4.  Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.

Authors:  Hemanth Naick Banavath; Om Prakash Sharma; Muthuvel Suresh Kumar; R Baskaran
Journal:  Sci Rep       Date:  2014-11-10       Impact factor: 4.379

Review 5.  Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment.

Authors:  Agnieszka Wieczorek; Lutz Uharek
Journal:  Biomark Insights       Date:  2016-02-18

6.  Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.

Authors:  Dany A Curi; Elspeth M Beauchamp; Gavin T Blyth; Ahmet Dirim Arslan; Nicholas J Donato; Francis J Giles; Jessica K Altman; Leonidas C Platanias
Journal:  Oncotarget       Date:  2015-10-20

7.  Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.

Authors:  Evan Flietner; Zhi Wen; Adhithi Rajagopalan; Oisun Jung; Lyndsay Watkins; Joshua Wiesner; Xiaona You; Yun Zhou; Yuqian Sun; Brock Kingstad-Bakke; Natalie S Callander; Alan Rapraeger; M Suresh; Fotis Asimakopoulos; Jing Zhang
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.